Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
rare diseases
MedTech
Oxford Nanopore, SeqOne ink rare disease diagnostic partnership
The goal will be to provide an end-to-end platform that applies extra-long nanopore sequencing reads to whole genomes.
Conor Hale
Mar 15, 2024 3:10pm
AstraZeneca inks $800M buyout to snag phase 3 rare disease drug
Mar 14, 2024 9:47am
Biogen's top dealmaker is keen on rare disease meds
Mar 5, 2024 10:20am
After pair of failures, PTC finds path for Friedreich ataxia med
Mar 1, 2024 9:20am
Applied claims victory in phase 3 SORD fight, plots path to FDA
Feb 15, 2024 10:10am
Layoffs, end of line for Synlogic after PKU drug's phase 3 fail
Feb 9, 2024 7:11am